Akero Therapeutics, Inc
Clinical trials sponsored by Akero Therapeutics, Inc, explained in plain language.
-
New drug could slow liver scarring in NASH cirrhosis patients
Disease control Recruiting nowThis study tests a drug called efruxifermin in about 2,150 adults with liver cirrhosis (severe scarring) caused by NASH/MASH, a type of fatty liver disease. Participants will receive either the drug or a placebo to see if it can prevent serious liver events and improve fibrosis. …
Phase: PHASE3 • Sponsor: Akero Therapeutics, Inc • Aim: Disease control
Last updated May 26, 2026 11:33 UTC
-
New drug could stop liver scarring in its tracks
Disease control Recruiting nowThis study tests an experimental drug called efruxifermin in 1650 adults with a type of liver disease (NASH/MASH) and moderate liver scarring. The goal is to see if the drug can reverse the scarring and prevent serious liver problems like liver failure or need for a transplant. P…
Phase: PHASE3 • Sponsor: Akero Therapeutics, Inc • Aim: Disease control
Last updated May 26, 2026 11:31 UTC